Ask AI
Histology in CD
Interactive Case Challenge 3: Evolving Role of Histology in Crohn’s Disease Management 

Released: March 18, 2025

Activity

Progress
1
Course Completed

  1. Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171-185. 
  2. Ferrante M, D'Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423-2436. 
  3. Magro F, Jairath V, De Hertogh G, et al. DOP054 Early histologic response and remission are associated with objective control of inflammation after one year of treatment with mirikizumab in moderately-to-severely active Crohn’s disease. J Crohns Colitis. 2025;19(suppl_1):i190-i191. 
  4. Christensen B, Erlich J, Gibson PR, et al. Histologic healing is more strongly associated with clinical outcomes in ileal Crohn’s disease than endoscopic healing. Clin Gastroenterol Hepatol. 2020;18:2518-2525. 
  5. Villanacci V, Del Sordo R, Mino S, et al. Histological healing in IBD: Ready for prime time? Dig Liver Dis. 2025;[Epub ahead of print]. 
  6. Magro F, Sabino J, Rosini F, et al. ECCO position on harmonisation of Crohn’s disease mucosal histopathology. J Crohns Colitis. 2022;16:876-883.